中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
Chinese Journal of Practical Ophthalmology
2015年
10期
1119-1122
,共4页
王璐璐%祝磊%张月琴%王丽娅
王璐璐%祝磊%張月琴%王麗婭
왕로로%축뢰%장월금%왕려아
睑板腺功能障碍%睑缘炎%四环素%治疗
瞼闆腺功能障礙%瞼緣炎%四環素%治療
검판선공능장애%검연염%사배소%치료
Meibomian gland dysfunction%Oculentum tetracycline et cortisone%Treatment outcome
目的 观察并评价四环素可的松眼膏局部应用治疗睑板腺功能障碍的安全性及有效性.方法 临床病例对照研究.收集2014年2～8月在河南省眼科研究所门诊就诊的睑板腺功能障碍患者84例,分别对每位患者进行眼部症状及体征评价(其中眼部体征评价项目包括结膜充血、泪膜碎屑、睑缘充血、睑板腺开口、睑板腺分泌物)、Schirmer Ⅰ试验、泪膜破裂时间、角膜荧光素染色、眼压、红外线睑板腺照相、泪液渗透压检查.患者应用数字表法随机分为两组,对照组每天热敷眼睑并每天使用人工泪滴眼液4次.治疗组每天涂抹四环素可的松眼膏于睑缘睑板腺开口处2此,其余方法相同.治疗1个月后复查.结果 治疗4周后,两组患者眼部症状及体征评价、Schirmer Ⅰ试验、泪膜破裂时间、角膜荧光素染色、泪液渗透压检查结果均较治疗前有所改善,差异有统计学意义(P＜0.05).而睑板腺成像分级评价差异无统计学意义(P＞0.05).治疗4周后,治疗组患者眼部症状及体征评价、Schirmer Ⅰ试验、泪膜破裂时间、角膜荧光素染色和泪液渗透压检查结果与对照组比较差异均有统计学意义(P＜0.05).Schirmer Ⅰ试验、眼压与治疗前无比较差异无统计学意义(P＞0.05).结论 四环素可的松眼膏局部涂抹于睑缘睑板腺开口处,配合热敷及睑板腺按摩,可明显改善睑板腺功能障碍症状及体征.
目的 觀察併評價四環素可的鬆眼膏跼部應用治療瞼闆腺功能障礙的安全性及有效性.方法 臨床病例對照研究.收集2014年2～8月在河南省眼科研究所門診就診的瞼闆腺功能障礙患者84例,分彆對每位患者進行眼部癥狀及體徵評價(其中眼部體徵評價項目包括結膜充血、淚膜碎屑、瞼緣充血、瞼闆腺開口、瞼闆腺分泌物)、Schirmer Ⅰ試驗、淚膜破裂時間、角膜熒光素染色、眼壓、紅外線瞼闆腺照相、淚液滲透壓檢查.患者應用數字錶法隨機分為兩組,對照組每天熱敷眼瞼併每天使用人工淚滴眼液4次.治療組每天塗抹四環素可的鬆眼膏于瞼緣瞼闆腺開口處2此,其餘方法相同.治療1箇月後複查.結果 治療4週後,兩組患者眼部癥狀及體徵評價、Schirmer Ⅰ試驗、淚膜破裂時間、角膜熒光素染色、淚液滲透壓檢查結果均較治療前有所改善,差異有統計學意義(P＜0.05).而瞼闆腺成像分級評價差異無統計學意義(P＞0.05).治療4週後,治療組患者眼部癥狀及體徵評價、Schirmer Ⅰ試驗、淚膜破裂時間、角膜熒光素染色和淚液滲透壓檢查結果與對照組比較差異均有統計學意義(P＜0.05).Schirmer Ⅰ試驗、眼壓與治療前無比較差異無統計學意義(P＞0.05).結論 四環素可的鬆眼膏跼部塗抹于瞼緣瞼闆腺開口處,配閤熱敷及瞼闆腺按摩,可明顯改善瞼闆腺功能障礙癥狀及體徵.
목적 관찰병평개사배소가적송안고국부응용치료검판선공능장애적안전성급유효성.방법 림상병례대조연구.수집2014년2～8월재하남성안과연구소문진취진적검판선공능장애환자84례,분별대매위환자진행안부증상급체정평개(기중안부체정평개항목포괄결막충혈、루막쇄설、검연충혈、검판선개구、검판선분비물)、Schirmer Ⅰ시험、루막파렬시간、각막형광소염색、안압、홍외선검판선조상、루액삼투압검사.환자응용수자표법수궤분위량조,대조조매천열부안검병매천사용인공루적안액4차.치료조매천도말사배소가적송안고우검연검판선개구처2차,기여방법상동.치료1개월후복사.결과 치료4주후,량조환자안부증상급체정평개、Schirmer Ⅰ시험、루막파렬시간、각막형광소염색、루액삼투압검사결과균교치료전유소개선,차이유통계학의의(P＜0.05).이검판선성상분급평개차이무통계학의의(P＞0.05).치료4주후,치료조환자안부증상급체정평개、Schirmer Ⅰ시험、루막파렬시간、각막형광소염색화루액삼투압검사결과여대조조비교차이균유통계학의의(P＜0.05).Schirmer Ⅰ시험、안압여치료전무비교차이무통계학의의(P＞0.05).결론 사배소가적송안고국부도말우검연검판선개구처,배합열부급검판선안마,가명현개선검판선공능장애증상급체정.
Objective To observe the efficacy and safety of oculentum tetracycline et cortisone in the treatment of meibomian gland dysfunction.Methods Totally 84 meibomian gland dysfunction patients (168 eyes) enrolled in our hospital from February 2014 to August 2014 were randomly divided into two groups: the experimental group (Oculentum tetracycline et cortisone group) and the control group.Hot compress (2 times/day) and Sodium hyaluronate eye drop (4 times/day) was applied for the patient in the control group.In addition oculentum tetracycline et cortisone was applied 2 times a day for the patient in the experimental group.Questionnaire, slit lamp microscope examination, fluorescent staining, tear break-up time (BUT) and Schirmer Ⅰ test (Slt) was used in these patients before the treatment and repeated one month after the treatment.The mean of the results were compared by t-tests.Results After 4 weeks of the treatment, the mean score of the questionnaire was significantly lower than that before the treatment in each group (texperimental =5.24, Pexperimental =0.00;tcon trol =4.25, Pcontrol =0.00).And the inflammation of the ocular surface was relieved obviously in both group (texperimental l =4.37, Pexperimental =0.00;tcontrol =3.19, Pcontrol =0.002).BUT was significantly prolonged in each group after the treatment (P ＜0.01).The mean score of the corneal fluorescein staining (FL) was lower than that before the treatment in each group.There was no significant change in ST Ⅰ or NCT in each group (P ＞0.05).Conclusions Topical oculentum tetracycline et cortisone is safe and effective for the treatment of meibomian gland dysfunction.
